To endow
RNAi molecules with drug-like properties, they need to be modified (for stabilization, immuno-silence, RISC incorporation). Modifications commonly used these days
include 2’-O-methyl and 2’-fluoro (2’-F) modification of the ribose sugar ring
and phosphorothioation of the phosphate connecting the constituent nucleotide monomers.
A study by
Ionis and AstraZeneca scientists now shows (Saleh et al 2018) that 2’-F nucleosides are
readily incorporated into RNA polymerase transcripts and the genome in tissue
culture cells. By contrast, 2’-MOE nucleosides, a modification that Ionis
chiefly uses for its antisense oligos, was highly refractory to such
incorporation under the same conditions.
So
regardless of the political motivation behind this publication- Ionis likes to paint the 2’-F modification used
by competitor Alnylam as dangerous, whereas Alnylam likes to say same about Ionis’
phosphorothioates- the fact that turnover products from RNAi
trigger degradation may be used in this way raises genotoxicity concerns that
need to be taken seriously.
Even if minor
degrees of 2’-F incorporations into transcripts and genomic and mitochondrial DNA turned out to be harmless, not undertaking the appropriate studies
could catch companies in the space on the backfoot when regulators suddenly
demand them.
It is
possible that RNAi bellwether Alnylam indeed has responded to this concern as they have taken to minimizing the 2’-F content in their latest generation of
GalNAc-conjugates while increasing 2’-O-methylation. Although Alnylam justified this change with wanting to further
increase the stability and thus longevity of the gene silencing, in light of
twice annual administrations already possible with the old format (see inclisiran
for PCSK9 lowering) and increasing 2'-O-methyl content making it harder to find intrinsically potent molecules, this move had me wondering whether it had actually to do
with toxicity concerns instead. This paper would
support this notion.
Does Arrowhead Pharmaceutical use either of these? If not what do they use?
ReplyDeleteYou can assume that Arrowhead is using these also for their latest conjugate platform.
ReplyDeleteDirk, is Arrowhead's TRiM likely to bypass this being potentially toxic if there are no issues with off targeting? TRiM appears very accurate and does not need endosomal escape due to this accuracy. Is this likely to translate to safety in this case?
ReplyDelete